Literature DB >> 7250176

Pharmacokinetics and biotransformation of benzbromarone in man.

H Ferber, H Vergin, G Hitzenberger.   

Abstract

After administration of a single oral dose of benzbromarone 100 mg to 7 subjects, the maximum serum level was 1.84 +/- 0.87 mg/l, and the elimination halflife was 2.77 +/- 1.07 h. The major metabolite, benzarone, could be detected in serum 3 h after administration of benzbromarone, and the maximum serum benzarone level of 0.79 +/- 0.21 mg/l occurred after 6 h. Benzarone had an elimination half-life from serum of 13.52 +/- 2.18 h. Both substances were excreted mainly via the liver and bile. In urine only benzarone beta-glucuronide could be detected; it amounted to 1.55% of the benzbromarone dose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7250176     DOI: 10.1007/bf00548587

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  [Treatment of hyperuricemic and gouty patients with derivatives of benzofuran].

Authors:  F Delbarre; C Auscher; J L Olivier; A Rose
Journal:  Sem Hop       Date:  1967-04-08

2.  Effect of single oral doses of benzbromarone on serum and urinary uric acid.

Authors:  A K Jain; J R Ryan; F G McMahon; R J Noveck
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

3.  Metabolism of benzbromarone in man.

Authors:  J Broekhuysen; M Pacco; R Sion; L Demeulenaere; M Van Hee
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

4.  [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].

Authors:  N Zöllner; A Griebsch; J K Fink
Journal:  Dtsch Med Wochenschr       Date:  1970-11-27       Impact factor: 0.628

5.  High-performance liquid chromatographic determination of benzbromarone and the main metabolite benzarone in serum.

Authors:  H Vergin; G Bishop
Journal:  J Chromatogr       Date:  1980-09-12

6.  [Research in the benzofuran series. 8. Transit of 2-ethyl-3-(4-hydroxybenzoyl)-benzofuran in man and animals].

Authors:  J Broekhuysen; J Bekaert; C Rozenblum; G Deltour
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-11

7.  Distal permeability to urate and effects of benzofuran derivatives in the rat kidney.

Authors:  R A Kramp; R Lenoir
Journal:  Am J Physiol       Date:  1975-03

8.  Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.

Authors:  T F Yu
Journal:  J Rheumatol       Date:  1976-09       Impact factor: 4.666

Review 9.  Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

  9 in total
  9 in total

1.  Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Variation of benzbromarone elimination in man--a population study.

Authors:  I Walter-Sack; U Gresser; M Adjan; I Kamilli; A Ittensohn; J X de Vries; E Weber; N Zöllner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; M Kohlmeier; E Weber
Journal:  Klin Wochenschr       Date:  1988-02-15

4.  The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits.

Authors:  H Iven; H Brasch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite.

Authors:  J X de Vries; I Walter-Sack; A Ittensohn; E Weber; H Empl; U Gresser; N Zöllner
Journal:  Clin Investig       Date:  1993-11

6.  Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.

Authors:  A A K El-Sheikh; J J M W van den Heuvel; J B Koenderink; F G M Russel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

Review 7.  A historical journey of searching for uricosuric drugs.

Authors:  Tim LThA Jansen; Giesen Tanja; Janssen Matthijs
Journal:  Clin Rheumatol       Date:  2021-09-28       Impact factor: 2.980

8.  SLC2A9 is a high-capacity urate transporter in humans.

Authors:  Mark J Caulfield; Patricia B Munroe; Deb O'Neill; Kate Witkowska; Fadi J Charchar; Manuel Doblado; Sarah Evans; Susana Eyheramendy; Abiodun Onipinla; Philip Howard; Sue Shaw-Hawkins; Richard J Dobson; Chris Wallace; Stephen J Newhouse; Morris Brown; John M Connell; Anna Dominiczak; Martin Farrall; G Mark Lathrop; Nilesh J Samani; Meena Kumari; Michael Marmot; Eric Brunner; John Chambers; Paul Elliott; Jaspal Kooner; Maris Laan; Elin Org; Gudrun Veldre; Margus Viigimaa; Francesco P Cappuccio; Chen Ji; Roberto Iacone; Pasquale Strazzullo; Kelle H Moley; Chris Cheeseman
Journal:  PLoS Med       Date:  2008-10-07       Impact factor: 11.069

9.  Identification of a Ligand Binding Pocket in LdtR from Liberibacter asiaticus.

Authors:  Fernando A Pagliai; Claudio F Gonzalez; Graciela L Lorca
Journal:  Front Microbiol       Date:  2015-11-25       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.